Compare Stocks

→ Protect Yourself While There’s Still Time … (From Weiss Ratings) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BLCM Bellicum Pharmaceuticals	$0.07 -6.6%	$0.08	$0.06 ▼ $1.31	$727K	1.39	22,874 shs	6,000 shs
FWP Forward Pharma A/S	$1.95	$2.17	$1.50 ▼ $6.48	$13.83M	1.38	7,484 shs	N/A
MLND Millendo Therapeutics	$3.48 +1.2%	$4.00	$0.92 ▼ $16.95	$66.27M	0.48	1.52 million shs	289,664 shs
PLXP PLx Pharma		$0.00	$0.02 ▼ $0.04	$603K	3.79	12.96 million shs	3,000 shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BLCM Bellicum Pharmaceuticals	0.00%	0.00%	0.00%	-22.29%	-77.74%
FWP Forward Pharma A/S	0.00%	0.00%	0.00%	0.00%	0.00%
MLND Millendo Therapeutics	+1.16%	+6.42%	-4.40%	-6.70%	+93.33%
PLXP PLx Pharma	0.00%	0.00%	0.00%	0.00%	-98.55%

Protect Yourself While There’s Still Time … (Ad)

The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.

4 simple steps to protect your privacy and money before it’s too late.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BLCM Bellicum Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
FWP Forward Pharma A/S	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MLND Millendo Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PLXP PLx Pharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BLCM Bellicum Pharmaceuticals	N/A	N/A	N/A	N/A
FWP Forward Pharma A/S	N/A	N/A	N/A	N/A
MLND Millendo Therapeutics	N/A	N/A	N/A	N/A
PLXP PLx Pharma	N/A	N/A	N/A	N/A

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BLCM Bellicum Pharmaceuticals	$1.50M	0.48	N/A	N/A	$0.23 per share	0.33
FWP Forward Pharma A/S	N/A	N/A	N/A	N/A	$10.09 per share	N/A
MLND Millendo Therapeutics	N/A	N/A	N/A	N/A	$1.78 per share	N/A
PLXP PLx Pharma	$4.54M	0.00	N/A	N/A	$1.30 per share	0.00

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BLCM Bellicum Pharmaceuticals	-$24.97M	N/A	0.00	∞	N/A	N/A	N/A	-157.93%	N/A
FWP Forward Pharma A/S	-$1.89M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
MLND Millendo Therapeutics	-$36.41M	N/A	0.00	∞	N/A	N/A	-91.03%	-72.44%	N/A
PLXP PLx Pharma	-$46.13M	-$1.85	N/A	N/A	N/A	-606.91%	-291.11%	-119.43%	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BLCM Bellicum Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
FWP Forward Pharma A/S	N/A	N/A	N/A	N/A	N/A
MLND Millendo Therapeutics	N/A	N/A	N/A	N/A	N/A
PLXP PLx Pharma	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BLCM Bellicum Pharmaceuticals	N/A	3.04	3.04
FWP Forward Pharma A/S	N/A	18.43	N/A
MLND Millendo Therapeutics	N/A	6.39	6.39
PLXP PLx Pharma	N/A	4.79	4.28

Ownership

Institutional Ownership

Company	Institutional Ownership
BLCM Bellicum Pharmaceuticals	4.93%
FWP Forward Pharma A/S	12.57%
MLND Millendo Therapeutics	N/A
PLXP PLx Pharma	21.19%

Insider Ownership

Company	Insider Ownership
BLCM Bellicum Pharmaceuticals	10.30%
FWP Forward Pharma A/S	71.47%
MLND Millendo Therapeutics	N/A
PLXP PLx Pharma	8.95%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
BLCM Bellicum Pharmaceuticals	13	9.72 million	8.72 million	Not Optionable
FWP Forward Pharma A/S	4	7.09 million	2.02 million	Not Optionable
MLND Millendo Therapeutics	12	19.04 million	N/A	Not Optionable
PLXP PLx Pharma	16	29.14 million	26.53 million	Not Optionable

MLND, FWP, PLXP, and BLCM Headlines

Source	Headline
	Protalix Biotherapeutics Inc (PLX) investing.com - January 30 at 9:00 AM
	Vertex Pharmaceuticals Inc VRTX morningstar.com - January 22 at 7:59 PM
	Vietnam National Petroleum Group (PLX) investing.com - October 23 at 10:13 AM
	PLx Pharma Inc (PLXPQ) uk.investing.com - August 21 at 4:54 AM
	Pharmaceutical R&D: the road to positive returns nature.com - July 16 at 9:22 AM
	PLXPQ PLx Pharma Inc. seekingalpha.com - April 21 at 11:49 PM
	PLx Pharma Inc. Enters into a Stalking Horse Asset Purchase Agreement to Sell VAZALORE(R) and Substantially All of its Assets marketwatch.com - April 13 at 10:45 PM
	Why PLx Pharma Shares Are Nosediving Today msn.com - April 12 at 4:03 PM
	Why iMedia Brands Shares Are Trading Higher By Over 13%; Here Are 20 Stocks Moving Premarket msn.com - April 12 at 10:33 AM
	Why PLx Pharma Shares Are Down Over 40% Tuesday msn.com - April 11 at 11:47 PM
	PLx Pharma Inc. Receives Nasdaq Delisting Notice finance.yahoo.com - April 11 at 6:43 PM
	Short Volatility Alert: Plx Pharma Inc msn.com - April 11 at 1:42 PM
	PLx Pharma's Return On Capital Employed Insights msn.com - December 22 at 2:37 PM
	PLx Pharma (PLXP) Q3 2022 Earnings Call Transcript seekingalpha.com - November 11 at 11:44 AM
	PLx Pharma down after Q3 revenue fell 94% Y/Y seekingalpha.com - November 11 at 11:44 AM
	PLx Pharma Inc. Reports Third Quarter 2022 Results and Provides Business Update finance.yahoo.com - November 10 at 8:33 PM
	PLx Pharma, Inc. (PLXP) Reports Q3 Loss, Misses Revenue Estimates finance.yahoo.com - November 10 at 8:33 PM
	Earnings Preview: PLx Pharma msn.com - November 10 at 3:32 PM
	PLx Pharma Inc. to Report Third Quarter 2022 Financial Results on November 11, 2022, and Provide Business Update finance.yahoo.com - October 26 at 12:57 PM
	Baseball Legend John Smoltz Featured on PLx Pharma’s Social Channels finance.yahoo.com - September 12 at 9:15 PM
	PLx Pharma Inc. (NASDAQ:PLXP) drops to US$21m and insiders who purchased earlier this year lose another US$52k finance.yahoo.com - September 5 at 11:30 AM
	PLXP Aug 2022 5.000 call finance.yahoo.com - August 20 at 9:18 PM
	PLx Pharma downgraded at Oppenheimer after Q2 miss seekingalpha.com - August 15 at 2:42 PM
	PLx Pharma to Explore Strategic Alternatives, Reduces Team marketwatch.com - August 12 at 11:28 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Bellicum Pharmaceuticals

NASDAQ:BLCM

Bellicum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen. Its clinical product candidates also include BPX-603, an autologous dual-switch GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing human epidermal growth factor receptor 2 antigen. It has collaboration and license agreements with Adaptimmune Therapeutics plc; Agensys, Inc.; BioVec Pharma, Inc.; ARIAD Pharmaceuticals, Inc.; and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was incorporated in 2004 and is based in Houston, Texas.

Forward Pharma A/S

NASDAQ:FWP

Forward Pharma A/S does not have significant operations. Previously, it operated as a biopharmaceutical company that focused on developing FP187 proprietary formulation of dimethyl fumarate for the treatment of inflammatory and neurological indications. Forward Pharma A/S was incorporated in 2005 and is headquartered in Copenhagen, Denmark.

Millendo Therapeutics

NASDAQ:MLND

As of June 25, 2021, Millendo Therapeutics, Inc. was acquired by Tempest Therapeutics Inc., in a reverse merger transaction. Millendo Therapeutics, Inc. operates as a biopharmaceutical company. The company is headquartered in Ann Arbor, Michigan.

PLx Pharma

NASDAQ:PLXP

PLx Pharma, Inc. is a late-stage specialty pharmaceutical company, which engages in the development and commercialization of technology platform for approved drugs. It offers PLxGuard delivery system, which uses surface acting lipids, such as phospholipids and free fatty acids, to modify the physiochemical properties of various drugs with a targeted release to select portions of the gastrointestinal (GI) tract. The company was founded by Ronald R. Zimmerman on November 12, 2002 and is headquartered in Sparta, NJ.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial